Adjuvant Opdivo Delays Recurrence in Advanced Melanoma Patients, CheckMate-238 Study Shows

Source: Immuno-Oncology News, September 2017

Advanced melanoma patients at high risk of recurrence after surgery fare better if given Opdivo (nivolumab) compared to the standard of care Yervoy (ipilimumab), according to data presented at the European Society for Medical Oncology (ESMO) 2017 Congress, in Madrid, Spain.

The findings from the CheckMate -238 Phase 3 trial (NCT02388906), featured in the poster “Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238),” show that Opdivo delayed disease recurrence compared to Yervoy, and induced fewer side effects.

The research also was published in the New England Journal of Medicine, in a study titled “Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.”

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories